Quantcast

Latest diabetic neuropathy Stories

2009-01-14 06:55:29

Scientist cautions that activities should be supervised closely by a medical professional More than 20 million Americans are living with diabetes, and that number is expected to increase by more than 5 million by 2010. One complication related to diabetes, Diabetic Peripheral Neuropathy, (DM+PN), can cause individuals to develop foot ulcers and, in extreme cases, amputation might be necessary. Previously, doctors and scientists have recommended that individuals with this complication stay off...

2008-12-08 08:29:42

It's now easier to know who should be tested for a common nerve disorder, when they should be tested, and how. Two new studies from Louisiana State University recommend new testing guidelines for neuropathy -- a degenerative nerve disorder. Researchers say a combination of certain screening blood tests and other specialized testing brings definitive information for certain forms of the disorder, while nerve biopsies may not be as useful in certain cases. "There are many people with a...

2008-11-12 09:00:10

DOYLESTOWN, Pa., Nov. 12 /PRNewswire-FirstCall/ -- Quigley Pharma Inc., a wholly-owned subsidiary of The Quigley Corporation announced today that the last subject in the Phase IIb Study is scheduled to complete treatment on November 25, 2008. This will effectively move the study to the final stage of data collection, evaluation and study conclusions. The Company, after collecting all the patient information from 21 Study centers and conferring with its panel of experts on the data, will...

2008-11-11 09:00:47

Sangamo BioSciences, a developer of novel DNA-binding proteins for therapeutic gene regulation and modification, has announced top-line data from its SB-509-601 clinical trial, one of Sangamo's three Phase II clinical studies from its ZFP therapeutic program to develop SB-509 for diabetic neuropathy. The study is a double-blind, placebo-controlled, repeat-dosing multi- center study designed to evaluate the clinical safety and clinical effects of repeat administration of SB-509 in diabetics...

2008-11-10 18:00:05

RICHMOND, Calif., Nov. 10 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. announced today top-line data from its SB-509-601 clinical trial, one of Sangamo's three Phase 2 clinical studies from its ZFP Therapeutic(TM) program to develop SB-509 for diabetic neuropathy (DN). The data demonstrate that repeat administration of the drug is well tolerated in subjects with mild to moderate DN. However, no significant differences were observed between the SB-509 and placebo treated subjects in...

2008-10-08 09:00:12

XTL Biopharmaceuticals, a developer of therapeutics for the treatment of diabetic neuropathic pain and hepatitis C virus, has announced that the last patient randomized into the Bicifadine Phase IIb clinical trial for the treatment of diabetic neuropathic pain has completed the study. This milestone officially marks the completion of this randomized, double-blind, placebo-controlled Phase IIb clinical trial which enrolled 351 patients at approximately 40 sites in the US, Germany, Israel and...

2008-09-15 12:00:35

RICHMOND, Calif., Sept. 15 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. announced today the presentation of positive interim Phase 2 clinical data from its ZFP Therapeutic(TM) program (SB-509-701) at the International Society for Cellular Therapy (ISCT) Europe Regional Meeting in Antwerp, Belgium. The data presented demonstrate an improvement in nerve conduction velocity (NCV) in SB-509 treated subjects with moderate to severe diabetic neuropathy (DN), a patient population that until...

2008-09-03 09:00:08

RICHMOND, Calif., Sept. 3 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. announced today that it has opened a Phase 2 clinical trial (SB-509-801) to evaluate its drug, SB-509, in subjects with ALS, a progressive, degenerative motor-neuron disease for which there are limited treatment options and no cure. Sangamo's drug, SB-509, is an injectable formulation of a plasmid encoding a zinc finger DNA-binding protein transcription factor (ZFP TF(TM)) designed to upregulate the expression...

2008-08-25 09:01:58

SUN VALLEY, Calif., Aug. 25 /PRNewswire-FirstCall/ -- XTend Medical Corporation (Pink Sheets: XMDC), a company that delivers cutting-edge telemedicine solutions to the healthcare industry, has secured the exclusive global distribution rights to DDI's Vibration Device for Pre-Screening of Diabetic Neuropathy. The company released the following statement: "XTend Medical is pleased to announce that we have secured the global distribution rights to DDI's patented vibration technology device,...

2008-08-25 09:01:58

XTend Medical has secured the exclusive global distribution rights to DDI's vibration device for pre-screening of diabetic neuropathy. Paul Lisenby, CEO of XTend Medical, said: "Once the FDA has cleared the device for sale, we will immediately begin marketing the product to our managed care companies and the various physicians and patients here in the US. We're also in negotiations to market the product in South Korea and Europe based on their separate criteria needs for final approval....


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related